Cell Medica Announces Orphan Drug Designation In The European Union For Cytovir ADV
1/7/2014 8:49:47 AM
LONDON--(BUSINESS WIRE)--Cell Medica Limited today announced that the European Medicines Agency’s (EMA) Committee for Orphan Medicinal Products has issued a positive opinion on an application for orphan designation of a novel T cell immunotherapy under development by the company. The cell therapy, Cytovir ADV, targets the treatment of adenovirus infections in patients following allogeneic hematopoietic stem cell (bone marrow) transplant and is comprised of adenovirus-specific T-cells derived from allogeneic donor leukocytes, expanded ex vivo. Adenovirus infections are a frequent cause of complications and death in patients, particularly children, who have received bone marrow transplants.
Help employers find you! Check out all the jobs and post your resume.
comments powered by